Triasima Portfolio Management inc. Buys 967 Shares of McKesson Corporation $MCK

Triasima Portfolio Management inc. raised its stake in shares of McKesson Corporation (NYSE:MCK) by 21.8% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 5,396 shares of the company’s stock after acquiring an additional 967 shares during the period. Triasima Portfolio Management inc.’s holdings in McKesson were worth $4,426,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in McKesson by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 12,104,719 shares of the company’s stock valued at $9,929,380,000 after acquiring an additional 73,109 shares during the period. State Street Corp lifted its stake in McKesson by 0.9% during the 3rd quarter. State Street Corp now owns 5,750,519 shares of the company’s stock valued at $4,447,110,000 after acquiring an additional 51,510 shares during the period. Franklin Resources Inc. lifted its stake in McKesson by 3.5% during the 3rd quarter. Franklin Resources Inc. now owns 2,681,321 shares of the company’s stock valued at $2,071,428,000 after acquiring an additional 90,948 shares during the period. Alliancebernstein L.P. lifted its stake in McKesson by 5.6% during the 3rd quarter. Alliancebernstein L.P. now owns 2,394,699 shares of the company’s stock valued at $1,850,001,000 after acquiring an additional 126,684 shares during the period. Finally, Northern Trust Corp lifted its stake in McKesson by 0.4% during the 3rd quarter. Northern Trust Corp now owns 1,532,856 shares of the company’s stock valued at $1,184,193,000 after acquiring an additional 6,613 shares during the period. Institutional investors own 85.07% of the company’s stock.

McKesson Trading Up 0.1%

McKesson stock opened at $814.69 on Monday. The firm has a 50 day moving average of $894.86 and a 200 day moving average of $860.34. The firm has a market capitalization of $99.79 billion, a price-to-earnings ratio of 23.43, a P/E/G ratio of 1.18 and a beta of 0.35. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.19 by $0.15. The company had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, analysts predict that McKesson Corporation will post 39.02 EPS for the current year.

McKesson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 1st. McKesson’s dividend payout ratio (DPR) is 9.43%.

Insider Activity at McKesson

In other McKesson news, EVP Michele Lau sold 2,725 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the completion of the sale, the executive vice president directly owned 3,247 shares of the company’s stock, valued at $3,214,530. This trade represents a 45.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Maria Martinez sold 349 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total transaction of $328,014.63. Following the sale, the director directly owned 301 shares of the company’s stock, valued at approximately $282,900.87. This trade represents a 53.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 3,592 shares of company stock valued at $3,518,555. Corporate insiders own 0.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on MCK shares. Morgan Stanley restated an “overweight” rating and set a $966.00 target price on shares of McKesson in a research note on Thursday, January 29th. TD Cowen upped their target price on shares of McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research note on Thursday, February 5th. Mizuho increased their price objective on shares of McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a research note on Thursday, February 5th. JPMorgan Chase & Co. increased their price objective on shares of McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Finally, Wells Fargo & Company increased their price objective on shares of McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 5th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $972.27.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.